FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)

View source ↗

Summary

The FDA approved a supplemental application for BLINCYTO (blinatumomab) submitted by Amgen, signaling an update to labeling and/or indications for use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

SUPPL AP for BLINCYTO (BLINATUMOMAB)